Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based studyAnnette Wigertz, Mats Lambe, Johan Ahlgren et al.|Breast Cancer Research and Treatment|2012Cited by 125
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX TrialHeikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|Journal of Clinical Oncology|2011Cited by 118
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast CancerHeikki Joensuu, Henrik Lindman, Greger Nilsson et al.|JAMA Oncology|2017Cited by 95
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialHeikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|The Lancet Oncology|2009Cited by 65
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort studyMaria Sund, Antonios Valachis, Miguel Garcia‐Argibay et al.|The Breast|2021Cited by 41